ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial

ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial

Introduction Both rituximab (RTX) and cyclophosphamide (CYC) are effectively used in combination with steroids as remission induction therapy for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Several studies have shown that the effect on achieving (clinical) r...

Full description

Bibliographic Details
Main Authors: Cees van Kooten, Y K Onno Teng, Willem Jan Bos, Obbo W Bredewold, Argho Ray, Jacqueline T Jonker, Hilde H F Remmelts, Ebru Dirikgil, Jolijn R van Leeuwen, Darius Soonawala, Bastiaan van Dam, Joris Rotmans, Ton Rabelink, Laura S van Dam
Format: Article
Language:English
Published: BMJ Publishing Group 2022-09-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/9/e061339.full

Internet

https://bmjopen.bmj.com/content/12/9/e061339.full

Similar Items